Today, cell and gene therapies can cure or transform many blood cancers and genetic diseases , but access is limited by cost, centralised manufacturing, and regulatory complexity. Most hospitals, especially in emerging regions, cannot raise the capital or build the systems required to participate.
Immuna changes this by acting as a full-stack implementation and commercialization partner for hospitals and health systems.
+41 79 889 81 63
Most hospitals lack the resources to raise funds or navigate regulatory hurdles. Immuna provides co-investment and revenue-sharing frameworks in hospitals with committed clinical leadership, using a Build–Own–Operate–Transfer (BOOT) model.
Immuna sets up regional manufacturing and quality hubs through BOOT to navigate complex supply chains and GMP bottlenecks, supporting local or near-site CAR-T and gene therapy production.
Immuna manages regional and global compliance and approvals, navigating fragmented regulatory systems so clinicians and hospitals can focus on care delivery instead of paperwork.
Immuna ensures commercialization and scalability via Swiss governance and operational efficiency, and takes responsibility for ROI accountability for hospital management through a hub-and-spoke model for regional rollout.
For more than three decades, the scientific leadership behind Immuna has been closely connected with pioneers who helped shape the field of cellular and gene therapy. Members of this ecosystem have contributed to the design and manufacturing of the world’s first clinically deployed lentiviral vectors—technologies that went on to support the first FDA-authorized immunotherapy trials using lentiviral delivery systems.
This deep technical lineage—spanning vector engineering, GMP manufacturing, regulatory engagement, and real-world clinical translation—forms the scientific foundation upon which Immuna is built. The experience accumulated over 30+ years across leading academic centres, biomanufacturing facilities, and clinical research programs ensures that Immuna’s platforms are grounded in rigorous science, proven technologies, and globally validated development pathways.
We work with multiple vendors, platforms, and equipment choices , always aiming for freedom-to-operate and affordability.
Local or regional GMP units integrated into health systems – not a single distant mega-facility.
Swiss-anchored governance with carefully designed pathways into Indian, African, ASEAN, GCC and Latin American regulatory systems.
For-profit, but mission-driven, with affordability and public health impact built into the model from day one.
Boro Dropulic
Boro holds a PhD from the University of Western Australia and an MBA from the Johns Hopkins University (JHU). He has been involved in gene therapy since the late 1980s.
Seeing a need for improved business models to support the affordability and accessibility of gene therapy products, Boro co-founded Caring Cross and serves as our Executive Director.
Pradeep Kakkattil
Global health and innovations leader. Co-founder of Health Innovation Exchange (HIEx) a unique platform connecting political leadership with innovators and investors for healthcare access which over last 2 years has facilitated over US200m in investments;
Co-founder of the Women in Innovation Fund (WiNFUND) which advocates, invests and supports acceleration of female health entrepreneurship in Africa and Asia;
Co-founder of Technical Support Facility (TSF) and built it to be the largest TA mechanism of the UN in HIV;
Dr. Biju Jacob
Experienced leader in innovation strategy, research infrastructure and start-up advisory with a decade of experience in early-stage discovery, clinical research and regulatory affairs. Worked in both large organizations and start-ups with deep medical research & management experience.
He is a recipient of BIRAC Innovation 2014 award, ISBA National award for entrepreneurship 2010 and CV Raman Young Scientist Awards 2007
Phani Sripada
Seasoned information security leader with over a decade of experience driving strategic initiatives at the intersection of Digital Transformation, Cybersecurity, Sustainability, and Corporate Digital Responsibility (CDR). As Chief Information Security Officer at Gavi, the Vaccine Alliance, I spearhead security strategies, risk management, and compliance to protect critical systems supporting global health and immunization.